| 0 (0%) | 11-30 07:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52 | 1-year : | 2.86 |
| Resists | First : | 2.16 | Second : | 2.45 |
| Pivot price | 1.9  |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 1.77  |
MA(20) : | 2.01 |
| MA(100) : | 1.87 |
MA(250) : | 2.02 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 12.6 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 3.09 | Low : | 1.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLX ] has closed above bottom band by 30.2%. Bollinger Bands are 37% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.87 |
| Low: | 1.77 - 1.78 | 1.78 - 1.79 |
| Close: | 1.82 - 1.83 | 1.83 - 1.84 |
Sun, 23 Nov 2025
Broadcom Shows the PEX90144 144 lane PCIe Gen6 Switch at SC25 - ServeTheHome
Fri, 21 Nov 2025
New Analyst Forecast: $PLX Given $12.0 Price Target - Quiver Quantitative
Fri, 21 Nov 2025
Protalix BioTherapeutics (PLX) Price Target Lowered by HC Wainwr - GuruFocus
Fri, 21 Nov 2025
HC Wainwright & Co. Maintains Protalix BioTherapeutics (PLX) Buy Recommendation - Nasdaq
Mon, 17 Nov 2025
PLX: Protalix Seeks Re-Examination of CHMP Opinion - Yahoo Finance
Thu, 06 Nov 2025
Protalix BioTherapeutics (NYSE American: PLX) sets Third Quarter 2025 call on Nov. 13 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 74 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 7.7 (%) |
| Shares Short | 3,420 (K) |
| Shares Short P.Month | 3,470 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | -38.7 % |
| Operating Margin | -18.1 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | -43.5 % |
| Qtrly Rev. Growth | -61.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -7.74 |
| PEG Ratio | 2.1 |
| Price to Book value | 4.56 |
| Price to Sales | 3.44 |
| Price to Cash Flow | -48.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|